Biogen Idec has submitted a biologics license application to the FDA for the use of recombinant factor IX Fc fusion protein as a treatment for hemophilia B. The company said a decision from the agency could come this year. Biogen Idec also said it is preparing to submit a similar application for a treatment for hemophilia A in the first three months of 2013.